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a  b  s  t  r  a  c  t
Bisphenol  A (BPA)  is a chemical  used  in  the  production  of numerous  consumer  products  resulting  in
potential  daily  human  exposure  to  this  chemical.  The  FDA  previously  evaluated  the body  of BPA  toxicology
data  and  determined  that  BPA  is  safe  at current  exposure  levels.  Although  consistent  with  the  assessment
of some  other  regulatory  agencies  around  the  world,  this  determination  of BPA  safety  continues  to  be
debated  in  scientiﬁc  and  popular  publications,  resulting  in  conﬂicting  messages  to  the  public.  Thus,  the
National  Toxicology  Program  (NTP),  National  Institute  of  Environmental  Health  Sciences  (NIEHS),  and
U.S. Food  and  Drug  Administration  (FDA) developed  a consortium-based  research  program  to  link  moreisphenol A
IEHS
DA
TP
LARITY-BPA
onsortium
ndocrine disruptors
effectively  a variety  of hypothesis-based  research  investigations  and  guideline-compliant  safety  testing
with BPA.  This  collaboration  is  known  as the  Consortium  Linking  Academic  and Regulatory  Insights  on
BPA  Toxicity  (CLARITY-BPA).  This  paper  provides  a  detailed  description  of  the  conduct  of the  study  and
a  midterm  update  on  progress  of  the CLARITY-BPA  research  program.
Published  by Elsevier  Inc. This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Data available for the assessment of the safety of chemi-
als often includes results from regulatory guideline-compliant
tudies performed or sponsored by government agencies or com-
ercial entities involved in the production or use of chemicals,
nd other studies characterized as hypothesis-driven generally
erformed by investigators in university settings. Funding for
he university-based investigators comes primarily from fed-
ral grants, although industry funding is not uncommon. The
ypothesis-driven, mechanistically focused studies are usually
mall in scale and often employ novel tools, up-to-date tech-
ologies, and various experimental models appropriate to study
asic mechanisms, developmental effects, and physiology. In
ontrast, guideline-compliant studies utilize validated endpoints
hat are conducted to meet regulatory and statutory mandates.
uideline-compliant studies are conducted under a rigorous set of
nternationally accepted procedures developed to ensure consis-
ency and standardization in the conduct and reporting of toxicity
tudies for regulatory purposes. Examples of such procedures
nclude guidelines described by the NTP [1] and the Organiza-
ion for Economic Cooperation and Development [2]. Such studies
re most often conducted to support pre-clinical safety screening
r for hazard identiﬁcation, dose-response, and safety evaluation.
n addition, when conducted for regulatory purposes, the studies
re conducted under Good Laboratory Practices (GLP) regulations
3] to ensure quality control and detailed record keeping. Both
uideline-compliant and hypothesis-driven research make valu-
ble contributions to our understanding of the potential adverse
ealth effects of chemical exposures [4].
Although BPA is a well-studied chemical, there are few existing
hronic toxicity data that include exposure during the perinatal
eriod or that include doses within an order of magnitude of the
evel of potential human dietary exposures (estimated by the FDA to
e less than 1 g/kg bw/day, [5]). Divergent ﬁndings and interpre-
ations of data from BPA toxicological studies exist. Indeed there
s a body of literature from hypothesis-driven studies that have
eported effects of low doses of BPA that constitute a hazard [6–8].
n the other hand, recent reviews of the data by regulatory agen-
ies continue to maintain that BPA is safe at current exposure levels
1,9,10]. To address these divergent views, NIEHS and FDA agreed
o perform a modiﬁed guideline-compliant chronic toxicity study,
onducted under GLP regulations at an FDA facility, and involve . . . .  .  . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . .  .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  43
university-based investigators who would share biological samples
from that study to pursue functional, morphological, and molecu-
lar endpoints that are not typically included in guideline-compliant
studies. The resulting consortium-based research program, called
Consortium Linking Academic and Regulatory Insights on Toxicity
of BPA (CLARITY-BPA), integrates government guideline-compliant
research with 13 NIEHS-funded university-based studies. The com-
prehensive evaluation of guideline-compliant validated endpoints
with additional endpoints in the frame of a common and robust
study design is expected to signiﬁcantly improve the interpreta-
tion of the wealth of data that is being generated by all consortium
partners, including the characterization of the dose response of the
effects observed and their interpretation in an integrated biolog-
ical context. Details about the primary goals and organizational
structure of the program have been previously described [11]. This
report provides more in-depth details of the guideline-compliant
study, the consortium logistics, and outlines the additional end-
points analyzed by those university-based researchers.
1.1. CLARITY-BPA program and general study design
The CLARITY-BPA program is a cooperative agreement, con-
ducted under the auspices of the National Toxicology Program
(NTP), between NIEHS-funded university-based researchers, staff
at the NIEHS Division of the National Toxicology Program (DNTP)
and Division of Extramural Research and Training (DERT), and staff
at the FDA’s National Center for Toxicological Research (NCTR). The
core chronic GLP study is being performed at the NCTR and con-
tains the essential elements of a guideline-compliant study, such
as standard protocols and endpoints typically considered by reg-
ulatory agencies in hazard identiﬁcation and risk assessment. The
core chronic study shares many of the elements of the subchronic
90 day study that preceded it [12], several of which differ from
previous guideline-compliant BPA studies, notably monitoring of
BPA levels in animal housing materials and use of direct gavage
dosing for postnatal exposure. This route of exposure was selected
because lactational transfer of BPA has been demonstrated to be
low in this model [13] and because direct ingestion of BPA leach-
ing from food containers or packaging materials is the exposure
of interest in infants. In addition, direct dosing during the neona-
tal period results in precise exposure levels. The core study also
included limited assessments of internal dosimetry at the lowest
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ested doses that build upon those reported for the subchronic 90
ay study [14]. In addition to the continuous daily dosing through-
ut the study, a stop-dose arm was included. In this stop-dose arm,
osing ended at weaning and the animals were assessed con-
urrently with the continuous dose animals. This design allows
omparisons of the treatment effects following gestational-
hrough-weaning exposure with those of gestation-through-
ifetime exposure and thus partially addresses the impact of early
xposure alone relative to lifetime exposure or adult-only contin-
ous exposure [15]. Five dose levels of BPA, spaced at log intervals
rom 2.5 to 25,000 g BPA/kg bw/day, were used to cover the wide
ange of doses over which BPA-induced effects have been reported
n the scientiﬁc literature. Because BPA binds to the estrogen recep-
or and many of its reported effects have been hypothesized to
e due to modulation of estrogen signaling, two dose levels of
he reference estrogen ethinyl estradiol (EE2) were also included.
he Sprague-Dawley rat from the NCTR colony was  the animal
odel used in the current study, similar to what was done in
he subchronic 90 day study [14]. This animal model has been
hown to be sensitive to estrogenic compounds, including EE2 and
enistein [16–21] and a comprehensive evaluation of the pharma-
okinetics of BPA across life stages has been reported in this strain
13,14,22–24].
University-based researchers submitted grant applications in
esponse to an NIEHS issued Funding Opportunity Announcement
RFA-ES-10-009). Grant applications were reviewed for scientiﬁc
erit by a Special Emphasis Panel convened by NIEHS. FDA scien-
ists were not involved in the selection of the projects or endpoints,
xcept to determine the feasibility of accomplishing the goals of
he projects within resource constraints (such as availability of
nimal room space and/or personnel). Thirteen applications were
unded; some modiﬁcations to the original proposals were required
o ﬁt within the resource constraints of the overall project. The
niversity-based researchers were provided animals and/or tissues
r serum from animals that were litter mates of the core study ani-
als; all animals were housed at NCTR and exposed to BPA under
dentical conditions. This integrated research plan was  intended to
liminate variance in institutional and environmental conditions
hat potentially exist between studies conducted in different labo-
atories and to leverage extensive evaluations of internal dosimetry
hroughout the life-stages in the chosen animal model [14].
.2. Dose selection
The subchronic 90 day BPA study conducted prior to CLARITY-
PA in part to select doses for the present study [12], included two
egative controls (naïve or non-treated; vehicle), seven equally
paced “low” doses of BPA doses between 2.5 and 2,700 g/kg
w/day, two “high” doses of BPA (100,000 and 300,000 g/kg
w/day), and two doses of the reference estrogen (0.5 and 5 g
E2/kg bw/day). In that study, there were clear adverse effects of
PA treatment at the two highest doses of 100,000 and 300,000 g
PA/kg bw/day, some of which were also seen in the EE2 groups.
tatistically signiﬁcant changes at the gene expression level of
iblings were detected in the “low BPA” dose range [25]. The bio-
ogical meaning of these changes is unclear. Modulation of the
evel of estrogen receptor transcripts was further identiﬁed in the
rain of female rats in this animal cohort in the “low BPA” dose
ange, although their neurobehavioral consequences are currently
nknown [26]. Similarly, in a separate study using identical expo-
ure conditions, statistically signiﬁcant effects on estrogen receptor
xpression in the hypothalamus and amygdala of PND 1 pups of
oth sexes [27] and increased volume of the sexually dimorphic
ucleus of the preoptic area in PND 21 males [28] were reported
ollowing gestational exposure to 2.5 and 25 g BPA/kg bw/day.
ased on those results and current estimates of human exposurexicology 58 (2015) 33–44 35
levels [5], it was agreed by CLARITY-BPA stakeholders that log-
spaced doses ranging from 2.5 to 25,000 g BPA/kg bw/day would
provide the essential information sought by the study. In addition,
in the subchronic 90 day study, both doses of EE2 showed clear
effects on multiple endpoints in females, while effects on males
were largely conﬁned to the higher 5 g EE2/kg bw/day dose group.
For the CLARITY-BPA study, the NIEHS-funded university-based
researchers felt that a high dose of 0.5 g EE2/kg bw/day and a
lower dose of 0.05 g EE2/kg bw/day would be most informative
regarding the sensitivity of the animal model to EE2. These were
the two  EE2 doses used in the CLARITY-BPA study.
2. Study conduct details
This section describes the study material evaluations, general
study design, and animal treatments that were conducted at the
NCTR to provide animals for the core chronic two  year study and
hypothesis-driven studies developed and performed by academic
scientists.
2.1. Bisphenol A (BPA), ethinyl estradiol (EE2), and vehicle
BPA (CAS 80-05-7, TCI America Portland OR, catalog B0494,
Lot 111909/AOHOK [air-milled], >99% pure) and EE2 (CAS 57-63-
6, Sigma-Aldrich Chemical Co. St Louis, MO,  catalog E4876, Lot
071M1492V, >99% pure) were used in these studies [12]. Purity
of both compounds was veriﬁed at 6-month intervals during the
study and again at the end of the core study at two years to conﬁrm
test article stability. The vehicle used to deliver BPA and EE2 was
0.3% aqueous carboxymethylcellulose (CMC). The CMC  powder was
obtained from Sigma–Aldrich (St. Louis, MO;  catalogue C5013, Lot
041M0105V).
2.2. Diet characterization
Veriﬁed Casein Diet 10 IF, 5k96, a soy- and alfalfa-free
diet provided in round pellets, -irradiated [Test Diets, Purina
Mills, Richmond, IN; catalog 1810069; http://www.labdiet.com/
cs/groups/lolweb/@labdiet/documents/web content/mdrf/mdi4/
∼edisp/ducm04 028427.pdf] was used to minimize phytoestrogen
exposure. Certiﬁcates of analysis (nutrients, selected vitamins
and minerals, microbiological and chemical contaminants) were
provided by the manufacturer for each lot of diet prior to ship-
ment. Extracts of each diet lot were monitored for BPA and
selected myco/phytoestrogens (daidzein, genistein, coumestrol,
and zearalenone) by liquid chromatography/tandem mass spec-
trometry (LC/MS/MS). None of the diet lots contained BPA above
the protocol-speciﬁed maximum of 5 ppb [12]. Similarly, no diet
lot contained phyto/mycoestrogens above the protocol-speciﬁed
maximum level (2 ppm for genistein and daidzein, and 0.05 ppm
for coumestrol and zearelenone).
2.3. Assessment of background levels of BPA in study materials
other than diet
Other study materials screened for BPA included drinking water
and extracts of animal bedding, polysulfone cage leachates, and the
CMC  dosing vehicle. In addition, the silicone water bottle stoppers
were analyzed in the subchronic 90-day study [12]. Except for one
batch of 0.3% CMC  solution, which was excluded from the study,
none of these materials had BPA levels detectable above the average
analytical blank levels determined from triplicate samples on each
day of analysis. Drinking water was evaluated every 3 months, and
extracts of each lot of bedding were assayed; one lot of bedding had
an unidentiﬁed contaminant that prevented BPA analysis and was
not used. Polysulfone cages without excessive wear and scratches
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Table 1
Number of animals/treatment group assigned to the interim (1 year) and terminal
(2  year) sacriﬁces of the core chronic BPA toxicity study.a
Group Arm (Continuous/Stop) 1 Year 2 Year
Male Female Male Female
Vehicle Continuous 22 23 50 50
Stop 20 20 50 50 (49)b
2.5 BPA Continuous 22 22 48 48
Stop 20 22 48 50
25  BPA Continuous 20 22 48 46
Stop 20 20 48 48
250  BPA Continuous 24 24 50 50
Stop 20 22 50 50
2500  BPA Continuous 20 20 50 50
Stop 20 20 50 50
25,000 BPA Continuous 22 24 46 46
Stop 22 22 46 46
0.05  EE2 Continuous 26 26 26 26
0.50  EE2 Continuous 26 26 26 26
a Animals were allocated to the interim or terminal sacriﬁce of the continuous or
stop dose arms of the study at weaning. There were no same sex litter mates in any
treatment group. The original protocol indicated 26 animals/sex/treatment group
for  the interim sacriﬁce and 50 animals/sex/BPA treatment group (26 for EE2 groups)
for  the terminal sacriﬁce. A shortfall in the number of pups available for the specialty
studies resulted in a change such that 20–26 animals/sex/treatment being allocated
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b In this group, one animal assigned was found to have been incorrectly sexed and
as  discarded on the day of allocation.
ere used, and random samples of cage leachates were analyzed
rior to the study start. BPA was not detectable in any of these
nalyses above the average analytical blanks.
.4. Dose groups
There were 14 treatment groups in the core study and 16 treat-
ent groups in the university-based studies, although some of the
atter studies requested fewer treatment groups (see Table 1 for a
etailed description of each study). Brieﬂy, there was  a vehicle con-
rol group (0.3% CMC), ﬁve BPA dose groups (2.5, 25, 250, 2,500, and
5,000 g/kg bw/day), and two EE2 dose groups (0.05 and 0.5 g/kg
w/day). Each of these eight dose groups was split into two sepa-
ate groups, a continuously dosed group and a stop dose group,
ith the latter having treatment terminated at weaning [postna-
al day (PND) 21; day of birth = PND 0]. The core chronic two year
tudy did not include the stop dose EE2 arm, due to insufﬁcient
hysical space, but this arm was included in the hypothesis-driven
tudies requiring a reference estrogen control. Additionally, one
eparate breeding produced vehicle controls and a BPA dose of
50,000 g/kg bw/day for additional evaluation of testes and epi-
idymal sperm in hypothesis driven studies.
.5. Preparation and analysis of dose formulations
BPA and EE2 doses were prepared in the vehicle, 0.3% CMC  in
utoclaved Nanopure water, and administered (5 ml/kg bw) daily,
even days a week. Homogeneity and stability of the dose prepara-
ions were determined prior to the study start in a manner similar
o what has been previously described [12]. Doses were prepared
n an as needed basis within the stability window and the prepa-
ations were periodically certiﬁed to be ±10% of the target dose. In
ddition, dosing preparations were analyzed at the end of the use
eriod for the initial batches of doses, periodically over the course of
he study, and after the last dosing to verify that the correct dosing
ormulations were administered to the study animals.oxicology 58 (2015) 33–44
Doses were administered by gavage with a modiﬁed Hamil-
ton Microlab® ML511C programmable 115 V pump (Hamilton Co.,
Reno, NV). Four separate dosing stations were used in each animal
room: (1) vehicle control, (2) 2.5, 25, and 250 g BPA/kg bw/day,
(3) 2500 and 25,000 g BPA/kg bw/day, and (4) 0.05 and 0.5 g
EE2/kg bw/day. Dosing was always conducted from the lowest to
highest dose on any given pump, and cleaning and maintenance of
the equipment were performed as described in Delclos et al. [12].
The accuracy of dose delivery from the pumps was assessed every
three months and established to be within 10% of the target volume
accuracy.
2.6. Animal source and housing conditions
All animal use and procedures for the core study were approved
by the NCTR Laboratory Animal Care and Use Committee and
conducted in an Association for Assessment and Accreditation of
Laboratory Animal Care (AALAC)-accredited facility. Throughout
the study, animal rooms were maintained at 23 ± 3 ◦C with a rel-
ative humidity of 50 ± 20% and food and water were available ad
libitum. All animal rooms were under a 12 h light/dark cycle, with
lights on at 6 AM,  except those used to house weaned animals for
the behavior study that were kept on a 12 h light/dark cycle, with
lights on at 11 AM to accommodate behavioral testing during the
dark phase. There was  a minimum of 10 room air changes/h in all
animal rooms. The source of the NCTR CD rats (Strain Code 23) used
was the NCTR Rodent Breeding Colony. These breeding-source rats
are routinely fed NIH-41 irradiated pellets (IRR. NIH-41, catalogue #
7919C, Harlan Laboratories, Madison, WI)  and housed in polycarbo-
nate cages with hardwood chip bedding (P.J. Murphy, Montville, NJ
and Lab Animal Supplies, Inc., Lewisville, TX) and water in poly-
carbonate water bottles while housed in the NCTR colony.
Six hundred male and 600 female weanling (circa PND 21) NCTR
CD rats were assigned to the study in ﬁve equal loads spaced four
weeks apart (Loads 1–5). In addition, 28 females were assigned to
a small separate breeding (herein referred to as “Load 0”). Once
assigned to the study, rats were fed pelleted irradiated Purina 5K96
feed (Test Diets, Purina Mills, Richmond, IN), housed in polysul-
fone cages ﬁtted with microisolator tops (Ancare, Corp, Bellmore,
NY) with hardwood chip bedding and provided Millipore-ﬁltered
water in glass water bottles with silicone stoppers (#7721 clear,
The Plasticoid Co., Elkton, MD).
Animal health was  monitored throughout the core study in
accordance with the Sentinel Animal Program at NCTR. Each ani-
mal  room contained sentinel rats for microbiological surveillance
and one sentinel animal per room was evaluated every 3 months
over the course of the study. In some cases, as advised by the NCTR
veterinary staff, the hardwood chip bedding of animals with exter-
nal skin lesions was replaced with Alpha-Dri bedding (Shepherd
Specialty Papers, Richland, MI;  certiﬁed at NCTR to have BPA lev-
els below the analytical LOD), a virgin cellulose product which was
free of wood pieces that tended to embed in wounds and exacerbate
inﬂammation. Such lesions were observed with similar frequencies
in vehicle controls and all treatment groups.
For all animals, cages were changed twice weekly. Glass water
bottles were changed at least once weekly to maintain a constant
supply. Throughout the study, cage racks were changed every two
weeks and cage locations on those racks were rotated every two
weeks.
2.7. Animal breeding, randomized allocation to study, and dosingA summary of the experimental design is presented in Fig. 1.
Approximately 2 weeks prior to mating, female breeders were ran-
domized to treatment groups stratiﬁed by body weight to produce
approximately equivalent mean body weights in each group. The
J.J. Heindel et al. / Reproductive Toxicology 58 (2015) 33–44 37
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Fig. 1. Schematic representation of the study design as described in the text. The
ontinuous and stop dose arms are not depicted.
re-mating assignment of dams to dose groups was necessitated by
he use of randomly cycling females and the 10 day mating period
escribed below. Male breeders were assigned to breeding pairs
ith the stipulation that no sibling or ﬁrst cousin mating was  per-
itted. Rats were mated at 10–14 weeks of age for females and
1–15 weeks of age for males. As indicated above, animals were
ated in ﬁve loads or cohorts spaced four weeks apart. The num-
er of pairs assigned to treatment groups in later loads was  adjusted
ased on the number of litters produced for the study from prior
oads. Mating was conducted as described in Delclos et al. [12],
xcept that solid-bottomed polysulfone cages with hardwood chip
edding were used rather than wire bottom cages and a subset of
he breeder males (2 cases) were held for remating with a different
emale that had lost their breeding males. A subset of male breeders
as kept, single housed, after mating for use in the hypothesis-
riven testes function study. Daily gavage dosing of the dams began
n gestation day (GD) 6 (GD 0 = sperm positive day) and continued
ntil the initiation of parturition.
Pups were not dosed on the day of birth (PND 0). Pups were ran-
omly culled to a maximum of ﬁve males and ﬁve females on PND
, with tissues from some culls used for hypothesis-driven studies.
hile a balanced sex ratio after culling was the goal, because the
tudies required more males than females, the sex distribution of
he cull was skewed toward males in later study loads. Litters with
ewer than 3 pups/sex and live litters born to dams earlier than GD
0 were excluded from the core study. Litters with at least 6 pups
t PND 1 that did not meet the minimum 3 pups/sex criterion were
sed in the hypothesis-based studies that did not have litter size
r sex ratio requirements. Pups with evident malformations (e.g.,
ydrocephalus) were also excluded from the study. Direct gavage
osing of the pups started on PND 1 after the litter was  culled.
or pups younger than PND 5, the gavage needle did not entered animal assessment times for core chronic and specialty studies are indicated;
the esophagus. Before weaning at PND 21, pups were weighed and
dosed daily until the scheduled day of removal (PND 15 or PND 21).
After weaning, pups were housed two per cage (except for those
assigned to the behavior studies, which were housed 2–3 per cage)
and either dosed daily until termination (continuous dose arm) or
held without further dosing (stop dose arm). Animals in the con-
tinuous dosing arm were weighed daily prior to dosing until PND
90 ± 3, after which they were individually weighed weekly. For ani-
mals in the stop dose arm, body weights were recorded at weaning
and weekly thereafter.
At weaning, up to a maximum of 3 pups/sex/litter were assigned
to the core chronic 2 year study. Same-sex littermates were not
assigned to the same combination of study dose arm and time of
sacriﬁce. Forty-six to 50 pups/sex/BPA dose group/dose arm and 26
pups/sex/EE2 dose group (continuous dose arm only) were assigned
to the 2 year study and 20–26 pups/sex/dose group were assigned
to the one year interim assessment (Table 1). The remaining pups
from those litters with more than 3 same-sex pups were assigned to
the hypothesis driven studies at PND 15 (for the thyroid endpoints
study) and at weaning.
An additional breeding (“Load 0”, not depicted in Fig. 1) was
conducted at the request of one academic researcher for addi-
tional evaluation of testes and epididymal sperm. Fourteen dams
were assigned to vehicle dose group and 14 dams were assigned
to 250,000 g BPA/kg bw/day and treated as described above. Pups
from 10 l per treatment group were then treated daily until PND
90.3. Animal identiﬁcation
Prior to mating, all F0 animals were identiﬁed by tail tattoo (Ani-
mal  Identiﬁcation and Marking Systems, Inc., Hornell, NY) with
3 tive Toxicology 58 (2015) 33–44
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Fig. 2. Serum BPA-G measurements in vehicle, 2.5, and 25 g BPA/kg bw/day ani-
mals from the BPA core chronic study. Vehicle (continuous and stop dose arms) and
BPA-dosed (continuous arm only) males and females were evaluated. At a single
time point within one week of termination at 12 months of age, rats from each of
the  5 housing rooms of the core chronic study and representing all 5 study loads were
sampled from the tail vein to provide approximately 0.5 ml of blood. The blood sam-
ple  from animals in the continuous dosing arm was drawn 15–60 min after gavage,
approximately Cmax following gavage administration [8]. Rats from the vehicle con-
trol stop dose arm were sampled at approximately the same time of the day. Serum
samples were analyzed by LC–MS/MS blinded to treatment group. The limit of detec-
tion  (LOD) was  established on each day of analysis and the range is indicated by the
two  horizontal lines on the graph. Red symbols indicate BPA-G measurements that
were <LOD and are indicated as 1/2 LOD. X-axis labels, their deﬁnitions, and number
of  animals sampled are as follows: 0 Cont F and 0 Cont M represent continuous dose
vehicle control females and males, respectively, n = 13/sex; 0 Stop F and 0 Stop M
represent stop dose vehicle control females and males, respectively, n = 10/sex; 2.58 J.J. Heindel et al. / Reproduc
heir unique cage number. F1 pups were initially numbered on their
acks with an indelible marker after culling on PND 1 and were
dentiﬁed quickly on PND 1 after the culling procedure and prior
o the start of postnatal weighing and dosing by paw tattoo with
 standard 4-paw pattern corresponding to the number indicated
n its back. The paw tattoo pattern and dam ID (cage number) pro-
ided unique identiﬁcation for preweaning pups. Retained F1 pups
ere marked by tail tattoo with their unique ID (cage number and
n additional digit to distinguish cage mates) after weaning on PND
1.
. In-life data collection
Morbidity/mortality checks were performed twice daily and
linical observations were recorded weekly or when a signiﬁcant
linical observation was noted. Body weights were obtained prior to
osing for dams from GD 6 through parturition and similarly for the
ups from PND 1, as described above. Feed consumption was mea-
ured weekly from the start of dosing for approximately the next
3 weeks and monthly afterward in the chronic 2 year study, pri-
arily to estimate consumption of background dietary BPA. Water
ntake was not measured. On the day of birth, the number of pups
live and dead was recorded, but there were no other manipula-
ions of the dam or litter. On PND 1, the number of pups alive and
ead, sex ratio, and live litter weight by sex were determined prior
o culling. These data will be reported as part of the core chronic 2
ear study report.
. Evaluation of the potential for unintentional exposure of
LARITY-BPA animals to BPA
After the start of the CLARITY-BPA study, it was found that naïve
nd vehicle control animals in the NCTR BPA subchronic 90 day
tudy had serum levels of BPA-glucuronide (BPA-G) similar to those
roduced by the lowest BPA dose of the study (2.5 g/kg bw/day)
14]. It was hypothesized that there had been an unintentional
xposure to BPA resulting from the housing of control animals
ith the two very high BPA doses (100,000 and 300,000 g/kg
w/day). Although the highest BPA dose in the CLARITY-BPA study
s 25,000 g BPA/kg bw/day (Loads 1–5), Load 0 animals were
reated with 250,000 g BPA/kg bw/day. Some of these Load 0 ani-
als were housed in the same rooms as the other CLARITY-BPA
nimals. In the absence of speciﬁc internal dosimetry measure-
ents, it was assumed that the CLARITY-BPA study animals housed
ith the Load 0 high BPA dose (250,000 g/kg bw/day) might have
erum levels of BPA-G above the limit of detection (LOD) of cur-
ently available analytical methods, while animals housed in rooms
ith the high BPA dose of 25,000 g/kg bw/day would have serum
evels of BPA-G below the LOD. Internal dosimetry data collected
n CLARITY-BPA study animals support this hypothesis: (1) serum
rom eight of 10 vehicle-only treated females taken at the PND 90
ecropsy after an overnight fast and co-housed in rooms with ani-
als dosed with 250,000 g BPA/kg bw/day had BPA-G detectable
bove the LOD [1.6 nM ± 0.8 (S.D.)]; (2) serum from 5 vehicle and 5
E2-dosed animals similarly taken at the PND 90 necropsy after a
–7 h fast, but co-housed in rooms with 25,000 g BPA/kg bw/day
s the highest dose, did not have detectable BPA-G (<LOD); (3) tail
ein blood from 5 untreated and unhandled sentinels co-housed
n rooms with 25,000 g BPA/kg bw/day as the highest dose at the
ime of blood collection did not contain detectable levels of BPA-G;
nd (4) serum from 1 year core chronic animals co-housed in rooms
ith 25,000 g BPA/kg bw/day as the highest dose and collected at
pproximately Cmax after dosing with vehicle, 2.5, or 25 g BPA/kg
w/day showed a clear and statistically signiﬁcant separation of
erum levels of BPA-G among the three dose groups (Fig. 2). Of theCont F and 2.5 Cont M represent continuous dose 2.5 g BPA/kg bw/day females and
males, respectively, n = 15/sex; 25 Cont F and 25 Cont M represent continuous dose
25  g BPA/kg bw/day females and males, respectively, n = 15/sex.
46 vehicle serum samples analyzed, only 3 had detectable levels
of BPA-G. Two  of these samples were within the range of the daily
LOD while the third vehicle sample with detectable levels of BPA-G
(3.5 nM)  was determined to be incorrectly labeled (Fig. 2). We  con-
tinue to follow this possible contamination issue. The CLARITY-BPA
animals housed in the same room as those dosed with 250,000 g
BPA/kg bw/day and the days of co-housing are known, because
individual animals can be tracked throughout the study using the
NCTR in-life software system; this information will help determine
if data from these animals have any inﬂuence on the outcome of a
particular endpoint in most studies.
5.1. Chronic study
The core chronic study was  conducted in compliance with the
Food and Drug Administration (FDA) Good Laboratory Practice for
the conduct of nonclinical laboratory studies (United States Code
of Federal Regulations Title 21, Part 58). An interim sacriﬁce was
conducted at 1 year of age (PND 365 ± 20) and the terminal sacriﬁce
was conducted at 2 years of age (PND 730 ± 20). The numbers of
animals designated for interim and terminal sacriﬁce in each dose
group are shown in Table 1.
Food, but not water, was removed from animals before sched-
uled necropsy. Animals were anesthetized with gaseous carbon
dioxide and blood was  collected from the retro-orbital sinus.
Standard hematology and clinical chemistry endpoints (NTP Spec-
iﬁcations, 2011 http://ntp.niehs.nih.gov/ntp/test info/ﬁnalntp
reprospecsmay2011 508.pdf), insulin, leptin, cardiac troponins
T and I, triiodothyronine (T3), thyroxine (T4), and thyroid-
stimulating hormone (TSH) were evaluated in the interim sacriﬁce.
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ll animals reaching the scheduled terminal date were subjected
o a full necropsy. Selected organs were weighed. Tissues not
peciﬁed for microscopic evaluation were processed to parafﬁn
lock and held for potential later evaluation. For tissues speciﬁed
or evaluation by the study pathologists, all dose groups were eval-
ated. All gross lesions were processed for histological evaluation.
he following organs were examined microscopically: adrenals,
orta (thoracic), bone marrow (femur), brain, right epididymis,
eart, kidneys, liver, 5th left mammary gland (inguinal, female and
ale), ovaries, oviduct, pancreas, parathyroid, pituitary, prostate
dorsolateral and ventral), seminal vesicles with coagulating gland,
pleen, right testis, thymus, thyroid, uterus, and vagina. For the
orsolateral prostate, 6 step sections cut at 100 m intervals were
valuated. Subsets of intermediate sections were collected and
tored unstained for potential additional evaluation. The left testis
as used for evaluation of testicular spermatid head counts. The
eft epididymis was used for epididymal sperm counts, morphol-
gy, and motility evaluations. Procedures for the 1 and 2 year
ecropsies were the same, except that the 2 year sacriﬁce does not
nclude clinical chemistry, hematology, organ weights, or sperm
valuations. The core chronic study data will be analyzed following
tatistical methods similar to those used in the subchronic 90
ay study [12]. Statistical comparisons will be conducted within
ex and, for data collected after weaning, within dosing arm
continuous dosing or stop dosing). The ﬁve BPA dose groups will
e compared to the vehicle control group. Similarly, the two  EE2
eference estrogen dose groups will be compared to the vehicle
ontrol.
. NIEHS-funded hypothesis-driven studies
Integration of molecular, cellular, morphological, and func-
ional endpoints examined by university-based researchers with
alidated endpoints could contribute additional information in
nderstanding the possible effects of BPA exposure. A major goal of
he CLARITY-BPA study was to determine if endpoints reported to
e affected by BPA by hypothesis-driven studies are reproducible
hen assessed under the controlled conditions of a guideline-
ompliant study. If reproducible, the study could determine if
he endpoints previously reported in hypothesis-driven studies at
imes shorter than two years, might lead to or be correlated with
dverse outcomes at later ages, such as 2 years of age.
The university-based researchers are responsible for conduct-
ng the laboratory experiments speciﬁed in their NIEHS-funded
rants and for analyzing and reporting their data. The dose groups,
ime points, sample size, and endpoints in these studies were
etermined by the individual university-based researchers. The
pecimens were provided by NCTR, and included live animals
behavior and erectile dysfunction studies only), tissues, and/or
erum. The behavior and erectile dysfunction assays were con-
ucted at the NCTR by staff from the university-based researcher
aboratories with assistance from NCTR scientists, while tissue and
erum samples were collected by NCTR staff and shipped to the
niversity-based research laboratories for further analyses. Staff
embers from the university-based research laboratory responsi-
le for the testis function study came to NCTR to process the freshly
arvested tissues prior to shipping.
Prior to the start of the study, the university-based researchers
rovided NCTR with requests for litter-of-origin speciﬁca-
ions (e.g., minimum litter size, sex ratio at birth), in life data
ollection (e.g., palpation of animals), and detailed instruc-
ions for animal and tissue removal (e.g., assessment of
strous cycle to determine day of sacriﬁce, fasting require-
ents) and sample collection and processing (e.g., organ
eighed or not, determination of estrous phase at termination,xicology 58 (2015) 33–44 39
tissue dissection, ﬁxation and freezing, need for
sterility or RNase-free conditions, gross lesion processing, serum
volume needed).
When possible, the biological samples for a variety of endpoints
were collected from the same animals and were shared among
university-based researchers, a feature that represents a unique
aspect of this project (Table 2). Sharing of multiple tissues per ani-
mal  allowed not only a signiﬁcant reduction in animal use, but
resulted also in a more robust study design, as it integrated a larger
number of often related endpoints collected per animal. On the
other hand, a disadvantage of the tissue sharing was that it pre-
cluded special treatments of animals that would have been useful
for other speciﬁc endpoints. The list of university-based researchers
and a general description of their endpoints has been published
[11]; below further details of the research hypothesis and speciﬁc
endpoints of each university-based researcher study are described,
as well as information on study coordination and on university-
based researchers data tracking and decoding.
6.1. Reproductive system effects
6.1.1. Male
6.1.1.1. Obstructive voiding disorder (Fred vom Saal, University of
Missouri). The purpose of this project is to determine if develop-
mental exposure to BPA results in periurethral gland enlargement
and urethral gland obstruction associated with obstructive void-
ing disorder in adulthood. The vom Saal group, in collaboration
with Dr. William Ricke at the University of Wisconsin-Madison,
is examining the periurethral gland structure using computer-
assisted reconstruction and morphometric analysis coupled with
gene expression collected via laser capture microscopy in PND 1
male pups exposed to all doses of BPA and EE2. A similar gene
expression analysis coupled with histopathology is being per-
formed on 1-year-old animals exposed to all doses of BPA and
EE2 (continuous dose arm only), to assess the effects of continued
exposure beginning during fetal life throughout postnatal life on
urethral obstruction at adulthood.
6.1.1.2. Testes function (Kim Boekelheide, Brown University). This
project aims to determine if addition of sophisticated morpholog-
ical and molecular endpoints to the core chronic study provides
increased sensitivity and more speciﬁc biomarkers of treatment-
related male reproductive effects. The Boekelheide group is
integrating data from the core chronic study with additional
morphological evaluations, genome-wide microRNA and transcrip-
tomic proﬁling, and determination of genomic DNA methylation
status from both the testis and sperm. Speciﬁcally, spermatid
head retention in seminiferous tubules, deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining in
testes to assess apoptotic germ cells in a stage speciﬁc manner,
altered sperm mRNA and microRNA proﬁles using whole-genome
arrays, and perturbed sperm DNA methylation proﬁles in CpG-
enriched regions using reduced representation bisulﬁte sequencing
are being examined [29,30]. Sperm molecular biomarkers of BPA
exposure will be developed from PND 90 and 1-year-old animals
across all BPA doses and the 250,000 g BPA/kg bw/day high dose
(Load 0) using genome-wide approaches. The high EE2 dose group
is being analyzed at the 1 year timepoint as well.
6.1.1.3. Erectile dysfunction (Nestor Gonzalez-Cadavid, University of
California, Los Angeles). This project aims to determine if devel-
opmental exposure to BPA induces erectile dysfunction and/or
affects the underlying penile corpora cavernosal histopathology.
At 6 months of age, animals in all continuous doses of BPA are
being subjected to cavernosometry and electrical ﬁeld stimulation
of the cavernosal nerve (EFS) to measure erectile function. Global
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Table 2
Summary of functional assays and specimens collected per animal set in the hypothesis-driven studies.
Animal set by
age at sacriﬁce
Functional assays and specimens collected at necropsy Other information
PND 1 Males: serum, brain, UGS with bladder
Females: serum, brain, ovary
Animals originated from litters with a minimum of 9 pups born and a
balanced sex ratio at birth (no more than two extra pups of either sex,
if  possible)
PND  15 Males and females: serum, brain, heart, ileum, liver, pituitary Additional animals were treated with vehicle or PTU
PND  21 Males: serum, heart, spleen, thymus
Females: serum, heart, mammary gland, ovary, spleen, thymus, uterus
PND 21 Females: serum, mammary gland
PND 90 Males: serum, eye, fat pads, heart, prostate, spleen
Females: serum, eye, fat pads, heart, mammary gland, ovary, spleen,
uterus
Animals were fasted 5–7 h prior to sacriﬁce and cycling females were
scheduled to be sacriﬁced at estrus
PND  90 Males: testes, epididymal sperm Additional animals were treated with vehicle or 250,000 g BPA/kg
bw/day
6  months Males: serum, brain, fat pads, heart, liver, pancreas, penis, prostate,
spleen
Females: serum, brain, fat pads, heart, liver, mammary gland, ovary,
pancreas, spleen, uterus
Animals were fasted 5–7 h prior to sacriﬁce and cycling females were
scheduled to be sacriﬁced at estrus
6  months Males: erectile function assessment, serum, brain, penis
1  year Males: serum, fat pads, heart, liver, pancreas, prostate, spleen
Females: serum, fat pads, heart, liver, ovary, pancreas, spleen, uterus
Animals were fasted 5–7 h prior to sacriﬁce and cycling females were
scheduled to be sacriﬁced at estrus.
1  year Males: prostate Animals were implanted with T + E at PND 90
1  year Males: testes, epididymal sperm
1 year Males: urinary tract Animals originated from litters with a minimum of nine pups born and
a  balanced sex ratio at birth (no more than two  extra pups of either
sex, if possible)
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ranscriptomic signatures are being obtained from smooth mus-
le cells cultured from the corpora cavernosa. Serum testosterone
nd estradiol are being measured at 6 months. Serum, brain, and
enile tissue from the 6 month (stop dose arm) and 12 month (con-
inuous dose arm) were collected and stored for possible analysis
epending on the results of the 6 month continuous arm samples.
he data will be integrated into other aspects of male reproduction
ssessed by other CLARITY-BPA researchers for a more holistic pic-
ure of possible treatment-related effects on the male reproductive
ystem.
.1.2. Female
.1.2.1. Ovarian dysfunction and abnormal hormone levels (Jodi
laws, University of Illinois at Urbana-Champaign). This project aims
o determine the potential of BPA to inhibit follicle growth and
nduce atresia, leading to low estradiol (E2) levels. The Flaws group
s examining the effect of BPA on follicle numbers, by assessing
ollicle growth and atresia, and on E2 metabolism, by assessing
ts synthesis and metabolism in rat ovaries. To accomplish these
oals, extensive histological evaluation of the numbers of healthy
nd dying germ cells, primordial follicles, primary follicles, pre-
ntral follicles, and antral follicles at PND 1, PND 21, 6 months,
nd 1 year are being conducted. All doses of BPA and EE2 are being
ssessed from the continuous and stop dosing arms of the study.
erum estradiol and progesterone levels at PND 21, 6 months, and
 year are being measured also.
.1.2.2. Neurobehavioral effects (Heather Patisaul, North Carolina
tate University; Cheryl Rosenfeld, University of Missouri). This
roject evaluates the potential for developmental exposure to BPA
o induce subtle transcriptional and epigenetic changes at birth in
he hypothalamus and hippocampus and to alter levels of anxiety
nd activity in juveniles and adults. On PND 1, serum testos-
erone and estradiol, global DNA methylation and transcriptomics,
ia RNAseq, are being assessed in micropunched sections of the
ypothalamus and hippocampus in the 2.5 and 2500 g/kg bw/day
PA dose groups in both sexes to identify potentially affected genes.
dditionally, several behavioral endpoints are being assessed inAnimals originated from litters with a minimum of 9 pups born and a
balanced sex ratio at birth (no more than two extra pups of either sex,
if  possible)
juvenile and adult animals dosed with 2.5, 25, and 2500 g BPA/kg
bw/day and 0.5 g EE2/kg bw/day through PND 21 (stop dose
arm). Juvenile animals are being tested using open ﬁeld and ele-
vated plus maze (EPM) apparatus, while adult behavioral testing
consists of assessment of anxiety and overall activity (EPM, zero
maze, and open ﬁeld) and spatial learning and memory (Barnes
maze). Juvenile brains are being examined for volume of sexually
dimorphic hypothalamic nuclei using stereology. Adult brains are
being assessed to determine if the gene expression and methyla-
tion changes that might be observed in the neonates persist into
adulthood.
6.1.2.3. Immune dysfunction (Norbert Kaminski, Michigan State Uni-
versity). This project aims to determine if BPA developmental
exposure results in altered immune competence at adulthood
in part through changes in leukocyte composition and function
through changes in estrogen receptors. The Kaminski group is
examining thymus function (weight, cellularity, viability, thy-
mus/bw ratio, and phenotyping for CD3+, CD4+, CD8+and NK
cells) at PND 21 and spleen function (weight, cellularity, viability,
spleen/bw ratio, and phenotyping for CD3+,CD4+, CD8+, NK cells,
NKT cells, CD11b+, CD11c+, CD127a+, MHCII+, surface Ig) at PND21,
PND 90, 6 months, and 1 year in both sexes and all BPA and EE2
doses, in the continuous dosing arm. The Kaminski group is also
quantifying potential changes in estrogen receptors (ER) expression
(ER alpha and beta, G-protein-coupled ER, and ER-related recep-
tor gamma) and estrogen-sensitive genes known to be involved
in leukocyte function in unstimulated naïve splenic immune cell
populations and in activated (LPS) leukocytes isolated from BPA
treated rats.
6.1.2.4. Metabolic disease (Andrew Greenberg and Beverly Rubin,
Tufts University). This project is examining the potential for
developmental BPA exposure to facilitate the development of
dysregulated glucose and insulin metabolism at adulthood with
potential insulin resistance, type 2 diabetes mellitus, and altered
lipid metabolism that could lead to non-alcoholic fatty liver disease
(NAFLD). The Greenberg and Rubin groups are examining blood
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lucose and insulin levels at 1 year and possibly 6 months of age
n the continuous and stop dose arms using all BPA and EE2 dose
roups. Pancreas histology is being assessed also to determine islet
ell mass. Additionally, the potential chronology and progression
f hepatic lesions at 1 year and possibly 6 months of age and the
ipogenic, oxidative, and inﬂammatory gene expression and lipid
ccumulation are being assessed in the liver. Those data will be
iewed in relation to the serum measurements of glucose and
nsulin, adipose tissue weights, adipokines and serum fatty acids,
riglycerides, and cholesterol levels (measured by other investiga-
ors). Sex differences are also being evaluated.
.1.2.5. Obesity (Nira Ben-Jonathan, University of Cincinnati). This
roject aims to determine the potential for chronic BPA exposure
o alter adipose tissue functions that result in metabolic dysregula-
ion, regardless of body weight changes. To address the possible
ffects of BPA on aspects of weight gain and metabolism, the
en-Jonathan group is examining weight gain and measuring the
ubcutaneous and visceral fat pad weights in males and females at
ND 90, 6 months, and 1 year after continuous BPA or EE2 dosing
all doses); body and fat pad weights were collected at necropsy by
he NCTR. Fat tissue is being examined immunohistochemically to
easure cellularity and macrophage inﬁltration. Gene expression
f 19 adipogenesis or lipid related genes is being measured, includ-
ng adiponectin, leptin, cytokines, receptors, transcription factors
nd enzymes related to lipid metabolism. Serum prolactin, leptin,
diponectin, and IL-6 are being evaluated at PND 90, 6 months, and
 year.
.1.2.6. Cardiovascular effects (Scott Belcher, University of Cincin-
ati). This project is investigating if BPA exposure can result in
ardiac pathology. The Belcher group is examining males and
emales at PND 21, PND 90, 6 months, and 1 year from all BPA
nd EE2 dose groups from the continuous and stop dose arms. Gen-
ral heart tissue structure, left ventricular free wall thickness, and
issue damage and ﬁbrosis are being evaluated. Cardiac hypertro-
hy is being measured by calculation of myocyte diameter and
olume. Fluorescently-labeled cell membrane surfaces will be iden-
iﬁed and extracellular surface measurements are being made by
mage analysis software.
.1.2.7. Thyroid effects on Brain and Intestine (R. Thomas Zoeller,
niversity of Massachusetts, Amherst). This project aims to deter-
ine the ability of BPA to disrupt thyroid hormone signaling
uring development. To test whether BPA antagonizes the thy-
oid hormone receptor (TR), the Zoeller group is evaluating several
ndpoints of thyroid hormone action in the developing brain (PND
5), including oligodendrocyte development [31], RC3 expression
n the hippocampus, thyrotropin-releasing hormone expression in
he hypothalamic paraventricular nucleus, and cerebellar histogen-
sis from all BPA and EE2 dose groups. These endpoints are known
o be driven by thyroid hormone [32]. The ileum is being evalu-
ted also given that the intestinal epithelium is sensitive to thyroid
ormone [33,34]. In addition, serum thyroid hormone levels (total
4 and TSH) are being evaluated. A parallel experiment with the
rug propylthiouracil (PTU), which causes a signiﬁcant decrease in
erum thyroid hormone, is also being conducted to evaluate the
ensitivity of the experimental model to perturbations in thyroid
ormone levels.
.1.3. Cancer
.1.3.1. Mammary (Ana Soto, Tufts University). This project aims to
etermine the effects of developmental BPA exposure on the devel-
pment of pre-neoplastic and neoplastic lesions and on prepubertal
PND21) mammary gland morphology, DNA methylation proﬁles,
nd alterations in gene expression. PND 21 data will be used toxicology 58 (2015) 33–44 41
assess their potential to serve as prognosticators of later patho-
logical outcomes. The Soto group is quantifying preneoplastic and
neoplastic lesions in mammary glands at PND 21, PND 90, and 6
months for all BPA and EE2 doses in the continuous and stop dose
arms. Representative samples of female rats were palpated weekly
by NCTR animal care staff from PND 50 to 6 months of age to inves-
tigate the development of mammary tumors. The Soto group is
examining prepubertal mammary gland morphology by morpho-
metrics at PND 21. Using this tool, 3D image reconstructions of
whole mounted PND 21 mammary glands are being generated to
provide detailed information on the gland morphology. Addition-
ally, DNA and RNA are being isolated from laser-captured PND 21
mammary epithelial cells or stromal cells for transcriptomal analy-
ses via RNAseq and assessment of global patterns of genomic DNA
methylation to deﬁne if DNA methylation proﬁles and concomi-
tant alterations of gene expression at PND 21 will be predictors of
potential adult pathological outcomes.
6.1.3.2. Uterus (Shuk Mei Ho, University of Cincinnati). This project
is examining the potential for BPA exposure at critical windows
of exposure, accompanied by life-long continuous exposure, to
increase the risk of uterine cancer in rats. The Ho group is examin-
ing all BPA and EE2 doses in the continuous dosing arm at 6 months
and 1 year in order to determine a potential dose response curve for
chronic BPA exposure and development of uterine lesions, uterine
atypical hyperplasia, and/or adenocarcinoma, along with evalua-
tions of cell proliferation and apoptosis. If a speciﬁc BPA dose results
in a high incidence of uterine lesions, that dose will be assessed
further using global methylation and transcriptomic analysis to
identify novel gene methylation targets driven by BPA and associ-
ated with uterine tumor and cancer development. If the expression
of certain genes is modiﬁed by BPA exposures, those genes will be
assessed at PND 21, PND 90, and 6 months to determine their pos-
sible relation to uterine tumor formation, as determined in the core
chronic study. By comparing the methylome/transcriptome in rat
uterus with that in the prostate (see Prins below), it may  be possi-
ble to evaluate if BPA exposure reprograms genes in a sex and/or
tissue speciﬁc manner.
6.1.3.3. Prostate (Gail Prins, University of Illinois at Chicago). This
project is determining if developmental BPA exposure alters devel-
opmental programing of the prostate epithelial stem cells leading
to increased susceptibility to prostate cancer later in life. The Prins
group is examining all BPA doses along with the 0.5 g EE2/kg
bw/day dose group and the continuous and stop dose arms to
determine if there are differences in prostate pathology due to the
longer dosing (1 year of age). Some animals were given testos-
terone + estradiol (T + E) implants at PND 90 because treatment
of rats with T + E implants has been reported to induce neoplas-
tic lesions in the prostate [35]. The potential for BPA to alter the
incidence of prostatic neoplastic lesions with and without this
hormone treatment is being assessed. Prostate pathology, epithe-
lial hyperplasia, and prostatic intraepithelial neoplasia lesions are
being examined at 1 year of age. DNA methylation and expres-
sion of selected EE2 and BPA reprogramed genes in lateral and
dorsal prostates are being assessed at 1 year in the stop dose
study to identify possible epigenetic reprograming present at
that time. To investigate further the mechanisms, stem/progenitor
cells are being isolated from prostates from vehicle, BPA (2.5,
25, or 250 g/kg bw/day) or EE2 (0.5 g/kg bw/day) treated 6
month-old rats (continuous dose arm only) and cultured using
a prostasphere assay [36,37]. Differences in prostasphere num-
bers, size, gene expression, and/or differentiation ability are being
evaluated after three passages in the absence and presence of
estradiol.
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.1.3.4. Study integration and coordination. The CLARITY-BPA pro-
ram is overseen by a Steering Committee, which sets consortium
olicies and resolves conﬂicts as needed. The Steering Committee
s empowered to recommend adjustments to accommodate new
nowledge and redirect the scientiﬁc focus of the university-based
tudies as necessary. The Steering Committee includes investiga-
ors representing each NIEHS-funded grant, the NCTR Principal
nvestigator responsible for the core study, a representative from
IEHS’s Division of Extramural Research and Training (DERT), a
TP representative responsible for coordinating the project, and
he NIEHS-DNTP and FDA-NCTR project ofﬁcers responsible for
dministering the interagency agreement that supports the core
tudy. In addition, an External Scientiﬁc Panel of three scientists
rovides overall programmatic guidance and offers advice in the
anagement and technical performance of the research.
The overall consortium policies were compiled into several doc-
ments prior to implementation and include the following:
1) Articles of Collaboration. This document describes the speciﬁc
roles of the Steering Committee and the External Scientiﬁc
Panel and contains guidelines for conﬂict resolution. It also
describes the details of necropsy and sample collection of
the animals for the university-based studies, how samples
would be coded, sample shipping, data storage and sharing, and
authorship and publication guidelines.
2) Publications Agreement. This document describes the pro-
cedures for reviewing of abstracts and manuscripts and the
acknowledgments and disclaimers to be included in each pub-
lication.
3) Transfer of Data to Chemical Effects in Biological Systems (CEBS)
database/CEBS Access Memo/Decoding Standard Procedures.
This document delineates the procedure for university-based
researcher’s data submission to CEBS and the follow-up proce-
dure for sample decoding and lists all expected datasets and
estimated timeline for data submission by each university-
based researcher. CEBS is a relational database at NIEHS that
houses public toxicogenomics data and maintains private
repositories before data are made public [38].
. Data tracking and coding/decoding of specimens
Specimens (tissues, serum, and/or live animals) were provided
y NCTR to university-based researchers for their analysis with-
ut information of the treatment group or dosing arm. In general,
pecimen identiﬁers were not grouped in any way; however, in
ertain instances, additional specimen information was provided
o individual university-based researchers, upon presentation of a
trong rationale of the need for such data. The requests for addi-
ional specimen information were submitted to the consortium’s
ecoding Team, which is composed of representatives of FDA-
CTR, FDA-CFSAN, NIEHS-DNTP, and NIEHS-DERT along with one
niversity-based researcher representative, which approved (or
enied) the request. Examples of approved additional specimen
nformation include grouping of the specimen identiﬁers per coded
ose group (e.g., need to pool samples or to balance coded dose
roups across experiment batches) and listing a subset of coded
dentiﬁers to match only a subset of coded dose groups (e.g., only
 particular subset of dose groups was to be analyzed). In two
nstances, partial sample decoding (i.e., grouping of identiﬁers per
oded dose group and identiﬁcation of the grouped identiﬁers as
ehicle, BPA, or EE2) was also granted in order to permit prelimi-
ary statistical analysis needed to design follow-up experiments.
he partial decoding information was provided to the request-
ng university-based researcher upon signing of a conﬁdentiality
greement.oxicology 58 (2015) 33–44
Serum and tissues collected from a given animal were each
labeled with a different set of identiﬁers; in addition, all tissues col-
lected from a given animal were labeled with the same identiﬁer.
This was  necessary to minimize the chance of specimen misla-
beling, due to the already complex logistics during necropsy. A
measure implemented in the 6 and 12 month time points, which
alleviated considerably the burden of shared decoding, was to re-
label the ﬁxed tissues with unique identiﬁers prior to shipping
to the university-based researcher laboratories. Frozen specimens
were not relabeled to avoid the potential for sample thawing and
resulting degradation.
Coded raw data, along with an explanation for any missing data,
were submitted by the university-based researchers to the CEBS
Administrator. As each data set was  received, the CEBS Adminis-
trator or designee performed a completeness check against NCTR’s
coded identiﬁer list. Missing data were documented in writing
and reported to the university-based researcher for resolution by
the Decoding Team. Once completed and upon approval by the
Decoding Team, the raw data sets were archived in a read-only
repository in CEBS. Once all expected data were submitted for a
given animal set, the data were decoded. For animal sets shared
by multiple university-based researchers, the data were decoded
upon archiving of all expected data from the multiple university-
based researchers; approval was required by the Decoding Team
and all university-based researchers before the decoding process
began. Decoding was performed by the CEBS Administrator using
the decoding information provided by NCTR that linked, where
applicable, the specimen identiﬁers with the treatment group, dos-
ing arm, litter of origin, sex, windows of overlap with Load 0, estrous
phase on the day of sacriﬁce, and body and organ weights. Accu-
racy was  veriﬁed by the CEBS Administrator by performing quality
assurance for data integrity and veriﬁcation of decoding informa-
tion. When the decoding process was  complete, approval for release
was granted by the Decoding Team. At this point university-based
researchers were provided access to the veriﬁed decoded data in
CEBS. For quality assurance purposes, all coded and decoded data,
correspondence, and the decoded identiﬁer lists remain archived
in CEBS.
8. Discussion
CLARITY-BPA is a large-scale, multi-year consortium with a goal
of bringing together the strengths of a guideline-compliant study
and hypothesis-driven studies. It makes additional use of animals
produced in guideline-compliant reproductive studies, since these
studies typically analyze one pup per sex per litter/time point.
The use of the otherwise surplus littermates to generate addi-
tional cellular, molecular, and disease-focused endpoints in the
hypothesis-driven experiments by university-based researchers
will result in a more powerful study design, with the potential to
integrate multiple, related endpoints because datasets are collected
using a common animal model, diet, and dosing regimen. The in-
life phase of the university-based research studies was completed
in January 2014, and the in-life phase of the core chronic study was
completed in January 2015. Many of the expected university-based
researcher datasets have been archived in CEBS and decoded, and
reporting of the data either in scientiﬁc meetings and through peer-
reviewed articles is ongoing. Data from the core chronic study is
expected to be publicly available by 2018. In addition, positive and
negative raw data from all studies are intended to be archived in
CEBS, along with information for each study animal on the load and
litter of origin, estrous cycle phase at sacriﬁce (for cycling females),
and windows of overlap with Load 0 (to enable identiﬁcation of
potential periods of unintentional exposure to environmental BPA)
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ill be made publically available at study completion to offer the
ossibility for others to conduct independent analyses.
Although the study is still ongoing, several lessons have been
earned thus far. Effective and open communication among consor-
ium participants during all phases of the study, from design to data
ollection to ﬁnal data analyses or presentation, has been critical
nd will continue through the public presentation and the publi-
ation of data. Representatives from all CLARITY-BPA stakeholders,
ncluding NIEHS-DERT, NIEHS-NTP, FDA-NCTR, FDA-CFSAN, and a
niversity-based researcher representative, met  by teleconference
eekly for the ﬁrst year of the study and approximately biweekly
or the remainder of the study to follow study progress and address
ny unforeseen problems. In addition, webinars with all CLARITY-
PA participants, including the External Scientiﬁc Panel, are held
eriodically to report the progress of chronic and other studies
nd to discuss consortium-wide issues. Given the large number
f participants in the consortium and the various timelines for
ata collection amongst the hypothesis-driven studies, it is essen-
ial to have speciﬁc rules and guidelines deﬁned at the onset of
he program. For CLARITY-BPA, we developed a set of articles of
ollaboration, conﬁdentiality statements, publication agreements,
emos  describing transfer of data to the CEBS database, and an
OP for decoding of all data, which have been critical to the func-
ioning of the program. This consortium research model may  be
seful for investigating BPA by shedding light on doses, endpoints,
nd methods that may  enhance the utility of traditional toxicology
tudy designs for investigating additional chemicals. It is also pos-
ible that future collaborative programs based on this model will
ncrease the impact of basic research and to chemical risk assess-
ents.
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